Publications

Niemann J, Woller N, Brooks J, Fleischmann-Mundt B, Martin NT, Kloos A, Knocke S, Ernst AM, Manns MP, Kubicka S, Wirth TC, Gerardy-Schahn R, Kühnel F. Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy. Nat Commun 2019;10(1):3236.Brooks J, Fleischmann-Mundt B, Woller N, Niemann J, Ribback S, Peters K, Demir IE, Armbrecht N, Ceyhan GO, Manns MP, Wirth TC, Kubicka S, Bernhardt G, Smyth MJ, Calvisi DF, Gürlevik E, Kühnel F. Perioperative, spatiotemporally coordinated activation of T and NK cells prevents recurrence of pancreatic cancer. Cancer Res 2018;78:475-488.Martin NT, Wrede C, Niemann J, Brooks J, Schwarzer D, Kühnel F*, Gerardy-Schahn R*. Targeting polysialic acid-abundant cancers using oncolytic adenoviruses with fibers fused to active bacteriophage borne endosialidase. Biomaterials 2018;158:86-94. *equal contribution.Gürlevik E, Fleischmann-Mundt B, Brooks J, Demir IE, Steiger K, Ribback S, Yevsa T, Woller N, Kloos A, Ostroumov D, Armbrecht N, Manns MP, Dombrowski F, Saborowski M, Kleine M, Wirth TC, Oettle H, Ceyhan GO, Esposito I, Calvisi DF, Kubicka S, Kühnel F. NK cells prevent local recurrence after postoperative chemotherapy of pancreatic cancer with Akt2-driven metastasis. Gastroenterology 2016;151:338-350.Woller N, Gürlevik E, Fleischmann-Mundt B, Knocke S, Kloos A, Geffers R, Manns MP, Kubicka S, Kühnel F. Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. Mol Ther 2015;23:1630-1640.Kloos A, Woller N, Gürlevik E, Ureche CI, Armbrecht N, Geffers R, Manns MP, Gerardy-Schahn R, Kühnel F. PolySia-specific retargeting of oncolytic viruses triggers tumor-specific immune responses and facilitates therapy of small cell lung cancer. Cancer Immunol Res 2015;3:751-763.Gürlevik E, Schache P, Goez A, Kloos A, Woller N, Armbrecht N, Manns M, Kubicka S*, Kühnel F*. Meganuclease-mediated virus self-cleavage facilitates tumor-specific replication. Mol Ther 2013;21:1738-1748. *equal contribution.Gürlevik E, Fleischmann-Mundt B, Armbrecht N, Longerich T, Woller N, Kloos A, Hoffmann D, Schambach A, Manns MP, Zender L, Kubicka S*, Kühnel F*. Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma. Hepatology 2013;58:1031-1041. *equal contribution.Woller N, Knocke S, Mundt B, Gurlevik E, Struver N, Kloos A, Boozari B, Schache P, Manns MP, Malek NP, Sparwasser T, Zender L, Wirth TC, Kubicka S*, Kühnel F*. Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J Clin Invest 2011;121:2570-2582. *equal contribution.Boozari B, Mundt B, Woller N, Strüver N, Gürlevik E, Schache P, Kloos A, Knocke S, Manns MP, Wirth TC, Kubicka S*, Kühnel F*. Proteasome inhibition during oncolytic infection improves antitumoral immunity and inhibits metastatic growth of HCC. Gut 2010;59:1416-1426. *equal contribution.